Identification of miRNA biomarker signature for diagnosis and monitoring of lung diseases (ALLmiR-Study)

Identification of miRNA biomarker signature for diagnosis and monitoring of lung diseases (ALLmiR-Study) - ALLmiR-Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018784

Enrollment

1000

Registered

2019-11-18

Start date

2019-09-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34 J84 D86 R91 J44

Interventions

Group 1: Patients with lung cancer. The patients are referred to the study when admitted to the clinic. After written consent to participate in the study, blood is taken (baseline blood about 5 ml). I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Male or female, =18 years old, Therapy naïve, Respiratory complaints, sufficient knowledge of German, Willingness to participate in study

Exclusion criteria

Exclusion criteria: Known infectious diseases (HIV, HCV, HBV), Advanced, curatively-treated cancer within last 5 years

Design outcomes

Primary

Measure	Time frame
The aim is to evaluate a novel, miRNA-based method for the improvement of the diagnosis of lung diseases in a cohort of patients with lung complaints ("all-comers").	—

Secondary

Measure	Time frame
Identification of microRNA biomarker for safe and successful therapy and identification of microRNA biomarkers for relapse monitoring.	—

Countries

Germany

Contacts

Public ContactMartin Reck

LungenClinic Großhansdorf GmbH

info@lungenclinic.de+49 4102 / 601 - 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026